Goldman Sachs Group Inc Beyond Spring Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$1.06 - $1.81 $93,318 - $159,345	-88,036 Reduced 83.34%	17,599 $17,000
Q3 2022 Nov 10, 2022	SELL	$1.06 - $1.81 $93,318 - $159,345	-88,036 Reduced 83.34%	17,599 $0
Q2 2022 May 14, 2024	BUY	$1.13 - $2.66 $119,367 - $280,989	105,635 New	105,635 $152,000
Q2 2022 Aug 15, 2022	BUY	$1.13 - $2.66 $1,717 - $4,043	1,520 Added 1.46%	105,635 $152,000
Q1 2022 May 16, 2022	SELL	$1.68 - $5.01 $399,532 - $1.19 Million	-237,817 Reduced 69.55%	104,115 $229,000

Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $1.13 Million - $4.73 Million	280,893 Added 460.19%	341,932 $1.55 Million
Q3 2021 Nov 10, 2021	BUY	$9.26 - $31.31 $565,221 - $1.91 Million	61,039 New	61,039 $962,000

5.44M

30.3K

1.8K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $95.4M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.